Comparison of humoral immune responses to epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus using a viral proteome microarray

Journal of Infectious Diseases

Volumn 204, Issue 11, 2011, Pages 1683-1691

  Zheng, Dasheng ^b,e   Wan, Jun ^d   Cho, Yong Gu ^b   Wang, Leyao ^b   Chiou, Chuang Jiun ^b   Pai, Shweta ^b   Woodard, Crystal ^c   Zhu, Jian ^c   Liao, Gangling ^b   Martinez Maza, Otoniel ^f   Qian, Jiang ^a,d   Zhu, Heng ^a,c   Hayward, Gary S ^a,b   Ambinder, Richard F ^a,b   Hayward, S Diane ^a,b  

^a Viral Oncology Program   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c Department of Pharmacology ^*  (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e WUHAN INSTITUTE OF VIROLOGY   (China)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BBRF PROTEIN; BGLF2 PROTEIN; BNRF1 PROTEIN; BORF2 PROTEIN; BRRF1 PROTEIN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; ORF38 PROTEIN; UNCLASSIFIED DRUG; VIL10 PROTEIN; VIRUS ANTIGEN; VIRUS PROTEIN;

AIDS RELATED KAPOSI SARCOMA; AIDS RELATED LYMPHOMA; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; B CELL LYMPHOMA; CLINICAL ARTICLE; CONTROLLED STUDY; EPSTEIN BARR VIRUS; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; KAPOSI SARCOMA; LYMPHOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN MICROARRAY; PROTEOMICS; VIRUS LOAD;

ANTIGENS, VIRAL; HERPESVIRUS 4, HUMAN; HERPESVIRUS 8, HUMAN; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HIV-1; HUMANS; IMMUNITY, HUMORAL; IMMUNOGLOBULIN A; LYMPHOMA, AIDS-RELATED; LYMPHOMA, B-CELL; PROTEIN ARRAY ANALYSIS; SARCOMA, KAPOSI; VIRAL LOAD;

EID: 80155198393     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir645     Document Type: Article

References (50)

1. Bagni R, Whitby D. Kaposi's sarcoma-associated herpesvirus transmission and primary infection. Curr Opin HIV AIDS 2009; 4:22-6.
2. Dollard SC, Butler LM, Jones AM, et al. Substantial regional differences in human herpesvirus 8 seroprevalence in sub-Saharan Africa: Insights on the origin of the ''Kaposi's sarcoma belt.'' Int J Cancer 2010; 127:2395-401.
3. Gao SJ, Kingsley L, Li M, et al. KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. Nat Med 1996; 2:925-8.
4. Pfeiffer RM, Wheeler WA, Mbisa G, et al. Geographic heterogeneity of prevalence of the human herpesvirus 8 in sub-Saharan Africa: clues about etiology. Ann Epidemiol 2010; 20:958-63.
5. Martin JN, Ganem DE, Osmond DH, Page-Shafer KA, Macrae D, Kedes DH. Sexual transmission and the natural history of human herpesvirus 8 infection. N Engl J Med 1998; 338:948-54.
6. Martro E, Esteve A, Schulz TF, et al. Risk factors for human herpesvirus 8 infection and AIDS-associated Kaposi's sarcoma among men who have sex with men in a European multicentre study. Int J Cancer 2007; 120:1129-35.
7. O'Brien TR, Kedes D, Ganem D, et al. Evidence for concurrent epidemics of human herpesvirus 8 and human immunodeficiency virus type 1 in US homosexual men: Rates, risk factors, and relationship to Kaposi's sarcoma. J Infect Dis 1999; 180:1010-7.
8. Ambinder RF, Cesarman E. Clinical and pathological aspects of EBV and KSHV infection. In: Arvin A, Campadelli-Fiume G, Moore PS, eds. Human herpesviruses biology, therapy, and immunoprophylaxis. New York: Cambridge University Press, 2007; 885-914.
9. Nguyen ML, Farrell KJ, Gunthel CJ. Non-AIDS-defining malignancies in patients with HIV in the HAART era. Curr Infect Dis Rep 2010; 12:46-55.
10. Thorley-Lawson DA, Duca KA, Shapiro M. Epstein-Barr virus: A paradigm for persistent infection - for real and in virtual reality. Trends Immunol 2008; 29:195-201.
11. Tierney RJ, Steven N, Young LS, Rickinson AB. Epstein-Barr virus latency in blood mononuclear cells: Analysis of viral gene transcription during primary infection and in the carrier state. J Virol 1994; 68:7374-85.
12. Borza CM, Hutt-Fletcher LM. Alternate replication in B cells and epithelial cells switches tropism of Epstein-Barr virus. Nat Med 2002; 8:594-9.
13. Hadinoto V, Shapiro M, Sun CC, Thorley-Lawson DA. The dynamics of EBV shedding implicate a central role for epithelial cells in amplifying viral output. PLoS Pathog 2009; 5:e1000496.
14. Laichalk LL, Thorley-Lawson DA. Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. J Virol 2005; 79:1296-307.
15. Hassman LM, Ellison TJ, Kedes DH. KSHV infects a subset of human tonsillar B cells, driving proliferation and plasmablast differentiation. J Clin Invest 2011; 121:752-68.
16. Yu F, Feng J, Harada JN, Chanda SK, Kenney SC, Sun R. B cell terminal differentiation factor XBP-1 induces reactivation of Kaposi's sarcomaassociated herpesvirus. FEBS Lett 2007; 581:3485-8.
17. Mesri EA, Cesarman E, Boshoff C. Kaposi's sarcoma and its associated herpesvirus. Nat Rev Cancer 2010; 10:707-19.
18. Dittmer DP, Hilscher CJ, Gulley ML, Yang EV, Chen M, Glaser R. Multiple pathways for Epstein-Barr virus episome loss from nasopharyngeal carcinoma. Int J Cancer 2008; 123:2105-2.
19. Fakhari FD, Dittmer DP. Charting latency transcripts in Kaposi's sarcoma- associated herpesvirus by whole-genome real-time quantitative PCR. J Virol 2002; 76:6213-3.
20. Cheng WM, Chan KH, Chen HL, et al. Assessing the risk of nasopharyngeal carcinoma on the basis of EBV antibody spectrum. Int J Cancer 2002; 97:489-92.
21. Fachiroh J, Schouten T, Hariwiyanto B, et al. Molecular diversity of Epstein-Barr virus IgG and IgA antibody responses in nasopharyngeal carcinoma: A comparison of Indonesian, Chinese, and European subjects. J Infect Dis 2004; 190:53-62.
22. Ng WT, Yau TK, Yung RW, et al. Screening for family members of patients with nasopharyngeal carcinoma. Int J Cancer 2005; 113:998-1001.
23. Davies DH, Molina DM, Wrammert J, et al. Proteome-wide analysis of the serological response to vaccinia and smallpox. Proteomics 2007; 7:1678-86.
24. Zhu H, Hu S, Jona G, et al. Severe acute respiratory syndrome diagnostics using a coronavirus proteinmicroarray. Proc Natl Acad Sci U S A 2006; 103:4011-6.
25. Zhu J, Liao G, Shan L, et al. Protein array identification of substrates of the Epstein-Barr virus protein kinase BGLF4. J Virol 2009; 83:5219-31.
26. Zhou FC, Zhang YJ, Deng JH, et al. Efficient infection by a recombinant Kaposi's sarcoma-associated herpesvirus cloned in a bacterial artificial chromosome: Application for genetic analysis. J Virol 2002; 76:6185-96.
27. Lin L, Lee JY, Kaplan LD, et al. Effects of chemotherapy in AIDSassociated non-Hodgkin's lymphoma on Kaposi's sarcoma herpesvirus DNA in blood. J Clin Oncol 2009; 27:2496-502.
28. Olsen SJ, Sarid R, Chang Y, Moore PS. Evaluation of the latencyassociated nuclear antigen (ORF73) of Kaposi's sarcoma-associated herpesvirus by peptide mapping and bacterially expressed recombinant western blot assay. J Infect Dis 2000; 182:306-10.
29. Fachiroh J, Stevens SJ, Haryana SM, Middeldorp JM. Combination of Epstein-Barr virus scaffold (BdRF1/VCA-p40) and small capsid protein (BFRF3/VCA-p18) into a single molecule for improved serodiagnosis of acute and malignant EBV-driven disease. J VirolMethods 2010; 169:79-86.
30. Dambaugh T, Hennessy K, Chamnankit L, Kieff E. U2 region of Epstein-Barr virus DNA may encode Epstein-Barr nuclear antigen 2. Proc Natl Acad Sci U S A 1984; 81:7632-6.
31. Corchero JL, Mar EC, Spira TJ, Pellett PE, Inoue N. Comparison of serologic assays for detection of antibodies against human herpesvirus 8. Clin Diagn Lab Immunol 2001; 8:913-21.
32. Zhu L, Wang R, Sweat A, Goldstein E, Horvat R, Chandran B. Comparison of human sera reactivities in immunoblots with recombinant human herpesvirus (HHV)-8 proteins associated with the latent (ORF73) and lytic (ORFs 65, K8.1A, and K8.1B) replicative cycles and in immunofluorescence assays with HHV-8-infected BCBL-1 cells. Virology 1999; 256:381-92.
33. Sauter M, Boos H, Hirsch F, Mueller-Lantzsch N. Characterization of a latent protein encoded by the large internal repeats and the BamHI Y fragment of the Epstein-Barr virus (EBV) genome. Virology 1988; 166:586-90.
34. Wang F, Petti L, Braun D, Seung S, Kieff E. A bicistronic Epstein-Barr virus mRNA encodes two nuclear proteins in latently infected, growthtransformed lymphocytes. J Virol 1987; 61:945-54.
35. Lin JC, Wang WY, Chen KY, et al. Quantification of plasma Epstein- Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 2004; 350:2461-70.
36. Lo YM, Chan LY, Lo KW, et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 1999; 59:1188-91.
37. Gartner BC, Kortmann K, Schafer M, et al. No correlation in Epstein- Barr virus reactivation between serological parameters and viral load. J Clin Microbiol 2000; 38:2458.
38. Tsang RK, Vlantis AC, Ho RW, Tam JS, To KF, van Hasselt CA. Sensitivity and specificity of Epstein-Barr virus IGA titer in the diagnosis of nasopharyngeal carcinoma: A three-year institutional review. Head Neck 2004; 26:598-602.
39. Stevens SJ, Smits PH, Verkuijlen SA, et al. Aberrant Epstein-Barr virus persistence in HIV carriers is characterized by anti-Epstein-Barr virus IgA and high cellular viral loads with restricted transcription. AIDS 2007; 21:2141-9.
40. Johannsen E, Luftig M, Chase MR, et al. Proteins of purified Epstein- Barr virus. Proc Natl Acad Sci U S A 2004; 101:16286-91.
41. Mbopi-Keou FX, Legoff J, Piketty C, et al. Salivary production of IgA and IgG to human herpes virus 8 latent and lytic antigens by patients in whom Kaposi's sarcoma has regressed. AIDS 2004; 18:338-40.
42. Niederman JC, Miller G, Pearson HA, Pagano JS, Dowaliby JM. Infectious mononucleosis. Epstein-Barr-virus shedding in saliva and the oropharynx. N Engl J Med 1976; 294:1355-9.
43. Pauk J, Huang ML, Brodie SJ, et al. Mucosal shedding of human herpesvirus 8 in men. N Engl J Med 2000; 343:1369-77.
44. Blackbourn DJ, Ambroziak J, Lennette E, Adams M, Ramachandran B, Levy JA. Infectious human herpesvirus 8 in a healthy North American blood donor. Lancet 1997; 349:609-11.
45. Pellett PE, Wright DJ, Engels EA, et al. Multicenter comparison of serologic assays and estimation of human herpesvirus 8 seroprevalence among US blood donors. Transfusion 2003; 43:1260-8.
46. Qu L, Jenkins F, Triulzi DJ. Human herpesvirus 8 genomes and seroprevalence in United States blood donors. Transfusion 2010; 50:1050-6.
47. Brooks L, Yao QY, Rickinson AB, Young LS. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol 1992; 66:2689-97.
48. Busson P, McCoy R, Sadler R, Gilligan K, Tursz T, Raab-Traub N. Consistent transcription of the Epstein-Barr virus LMP2 gene in nasopharyngeal carcinoma. J Virol 1992; 66:3257-62.
49. Heussinger N, Buttner M, Ott G, et al. Expression of the Epstein- Barr virus (EBV)-encoded latent membrane protein 2A (LMP2A) in EBV-associated nasopharyngeal carcinoma. J Pathol 2004; 203: 696-9.
50. Oh ST, Seo JS, Moon UY, et al. A naturally derived gastric cancer cell line shows latency I Epstein-Barr virus infection closely resembling EBV-associated gastric cancer. Virology 2004; 320:330-6.